10-Q: Cellectar Biosciences Reports Reduced Losses, Advances WM Drug

Cellectar Biosciences reported significantly reduced net losses and R&D expenses for the nine months ended September 30, 2025, while advancing its lead drug candidate, iopofosine I 131, with FDA Breakthrough Therapy Designation and positive EMA guidance for Waldenstrom macroglobulinemia.

Summary

• Net loss for the nine months ended September 30, 2025, was approximately $16.5 million, a substantial reduction from $42.2 million in the same period of 2024.
• Research and development expenses decreased by 58% to $8.3 million for the nine months ended September 30, 2025, compared to $19.9 million in 2024, primarily due to the conclusion of patient enrollment in the CLOVER WaM Phase 2b clinical trial.
• General and administrative expenses decreased by 53% to $8.9 million for the nine months ended September 30, 2025, from $19.1 million in 2024, driven by reduced pre-commercialization and personnel costs.
• Cash and cash equivalents stood at approximately $12.6 million as of September 30, 2025, down from $23.3 million at December 31, 2024.
• The company received FDA Breakthrough Therapy Designation for iopofosine I 131 as a radioconjugate monotherapy for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) on June 4, 2025.
• The European Medicines Agency (EMA) Scientific Advice Working Party (SAWP) advised on October 6, 2025, that filing for a Conditional Marketing Authorization (CMA) for iopofosine I 131 in post-BTKi refractory WM patients could be acceptable.
• The CLOVER WaM Phase 2 study met its primary endpoint with a major response rate (MRR) of 58.2% (95% CI [44.50%, 75.80%], p < 0.0001), exceeding the FDA's 20% statistical hurdle, and achieved an overall response rate (ORR) of 83.6% and a 7.3% complete remission (CR) rate in highly refractory WM patients.
• A 1:30 reverse stock split was effected on June 24, 2025.
• The company completed an underwritten public offering in July 2025, raising approximately $6.9 million in gross proceeds, and a warrant inducement in June 2025, raising approximately $2.5 million in gross proceeds.
• A subsequent warrant inducement on October 7, 2025, generated approximately $5.8 million in gross proceeds.

Sentiment

Score: 7

Explanation: The filing presents a mixed but generally positive outlook, driven by significant clinical and regulatory advancements for iopofosine I 131, particularly the FDA Breakthrough Therapy Designation and positive EMA guidance for WM, coupled with substantial reductions in operating losses and cash burn. However, the persistent 'going concern' warning and identified material weaknesses in internal controls temper the overall sentiment, indicating ongoing financial fragility and operational challenges that require careful monitoring and successful remediation.

Positives

• Significant reduction in net loss for the nine months ended September 30, 2025, to $16.5 million from $42.2 million in the prior year.
• Research and development expenses decreased by 58% and general and administrative expenses decreased by 53% for the nine months ended September 30, 2025, indicating improved cost control.
• FDA granted Breakthrough Therapy Designation for iopofosine I 131 for r/r WM, which can expedite development and review.
• EMA's SAWP advised that a Conditional Marketing Authorization (CMA) filing for iopofosine I 131 in post-BTKi refractory WM could be acceptable, potentially leading to commercial availability in Europe by 2027.
• The CLOVER WaM Phase 2 study for iopofosine I 131 in r/r WM met its primary efficacy endpoint with a 58.2% major response rate, significantly exceeding the FDA's 20% hurdle, and showed durable responses and a 7.3% complete remission rate.
• Positive data from the Phase 1 investigator-initiated study of iopofosine in combination with external beam radiation in recurrent head and neck cancer, showing a 64% complete remission rate and 73% overall response rate in 11 patients.
• The proprietary Phospholipid Drug Conjugate (PDC) platform has demonstrated potential for targeted delivery of various oncologic payloads and has led to successful collaborations.
• Successful capital raises through public offerings and warrant inducements, including approximately $6.9 million in July 2025 and $5.8 million in October 2025, providing additional liquidity.

Negatives

• The company has incurred significant recurring losses and used net cash in operations since inception, with an accumulated deficit of approximately $263.8 million as of September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern beyond the third quarter of 2026 without securing additional outside capital.
• Cash and cash equivalents decreased significantly from $23.3 million at December 31, 2024, to $12.6 million at September 30, 2025.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2024, and continued through September 30, 2025, leading to restatements of prior financial statements.
• The company's existing cash and cash equivalents are not sufficient to progress CLR 125 through a Phase 1b dose finding study preliminary data readout, requiring additional funding.
• Interest income decreased year-over-year due to declining rates and lower amounts of invested funds.

Risks

• The regulatory strategy for iopofosine I 131 may not result in approval by the FDA, EMA, or any other regulatory authority, as they have substantial discretion and may require additional studies or disagree with trial designs.
• Inability to raise additional funds required to execute the regulatory strategy for iopofosine I 131, including the initiation of the proposed Phase 3 confirmatory study for WM.
• EMA scientific advice is legally non-binding and does not guarantee final Conditional Marketing Authorization (CMA) approval for iopofosine I 131, and the EMA may still require additional clinical or nonclinical studies.
• Existing cash and cash equivalents are insufficient to progress CLR 125 through a Phase 1b dose finding study preliminary data readout, and additional funding may not be obtainable on acceptable terms or at all.
• Failure to secure additional funding could lead to the sale of the company or its assets, discontinuance of certain operations, a wind-down of operations, or filing for bankruptcy protection.
• Material weaknesses in internal control over financial reporting could result in a material misstatement of financial statements that would not be prevented or timely detected.

Future Outlook

The company plans to submit a New Drug Application (NDA) to the FDA for accelerated approval of iopofosine I 131 for WM once a confirmatory trial is underway and subject to sufficient funding. It also intends to pursue a Conditional Marketing Authorization (CMA) in Europe for iopofosine I 131 for post-BTKi refractory WM, with potential commercial availability as early as 2027. The company is prepared to initiate Phase 1 studies for CLR 125 (in TNBC) and CLR 225 (imaging and dose escalation), both contingent on obtaining additional financing. Management is actively exploring strategic alternatives, including partnerships, to advance its pipeline and secure necessary funding, and plans to implement cost-saving measures to preserve liquidity.

Management Comments

• "While management believes one or more of the Company’s product candidates will be approved and successfully commercialized in the marketplace, no assurance can be provided any products will be approved or commercialized in a profitable manner."
• "While management believes additional outside capital will be secured as needed, no assurance can be provided that additional outside capital will be secured, or secured on terms that are acceptable to the Company."
• "While management believes their plans will be successful, no assurance can be provided such plans will be effectively implemented over the next twelve months beyond the issuance date." (Regarding liquidity plans)
• "Management has concluded that the consolidated financial statements included in this Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America." (Despite material weaknesses)

Industry Context

Cellectar Biosciences operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting cancer treatments with its proprietary Phospholipid Drug Conjugate (PDC) platform. The focus on radioconjugates (PRCs) like iopofosine I 131, CLR 125, and CLR 225 positions the company in a growing segment of oncology that seeks targeted delivery to minimize off-target effects. The FDA's Breakthrough Therapy Designation for iopofosine I 131 in WM and positive EMA guidance highlight the significant unmet medical need in this specific patient population and the potential for novel therapies to gain expedited regulatory pathways. The company's strategy of exploring strategic partnerships and collaborations is a common approach for smaller biotech firms to leverage larger partners' resources for late-stage development and commercialization, especially given the high costs and risks associated with bringing new drugs to market.

Comparison to Industry Standards

• The 58.2% Major Response Rate (MRR) and 7.3% Complete Remission (CR) rate for iopofosine I 131 in the CLOVER WaM study for highly refractory Waldenstrom macroglobulinemia (WM) patients significantly exceed historic real-world data, which typically demonstrate a 4-12% MRR and a duration of response of approximately six months or less, even in less pretreated populations. This suggests a potentially superior efficacy profile compared to existing treatments for this challenging patient group.
• The observed durability of responses, with median duration of response not reached at 11.4 months of follow-up and 76% of patients remaining progression-free at a median of eight months, also appears to surpass the typical duration of response for current therapies in this refractory WM population.
• The 64% Complete Remission (CR) and 73% Overall Response Rate (ORR) in the Phase 1 investigator-initiated study of iopofosine I 131 combined with external beam radiation in recurrent head and neck cancer (HNC) patients (n=11) are strong initial signals, especially considering that six patients had multiple recurrences and one had metastatic disease, indicative of poor outcomes with standard approaches. This suggests a potential for enhanced patient outcomes compared to conventional re-irradiation strategies which often cause severe injury to normal tissue.
• The company's financial position, characterized by recurring losses and a 'going concern' warning, is common for early to late-stage biopharmaceutical companies that are pre-revenue and heavily invested in R&D. However, the identified material weaknesses in internal controls are a significant concern that deviates from best practices for public companies, regardless of stage.

Corporate Governance

Legal Proceedings

• The company may be involved in legal matters and disputes in the ordinary course of business, but it is not anticipated that the outcome of such matters will materially affect the company's financial statements.

Stakeholder Impact

• **Shareholders:** Potential for significant value creation if iopofosine I 131 gains regulatory approval and commercial success, especially given Breakthrough Therapy Designation and positive EMA guidance. However, ongoing dilution risk from future capital raises and the 'going concern' warning pose substantial risks to investment value. The reverse stock split also impacts share count and price per share.
• **Patients:** Positive clinical trial results for iopofosine I 131 in r/r WM and HNC, along with expedited regulatory pathways, offer hope for new, effective treatment options for difficult-to-treat cancers.
• **Employees:** Reduced general and administrative expenses suggest potential personnel adjustments, but ongoing R&D efforts indicate continued employment in core scientific and clinical roles. The remediation efforts for internal control weaknesses may lead to new hires in finance and accounting.
• **Creditors/Lenders:** The 'going concern' warning and reliance on future capital raises indicate elevated risk, which could impact the terms and availability of future debt financing.
• **Regulatory Bodies (FDA, EMA):** The company is actively engaging with these bodies, having received Breakthrough Therapy Designation and positive scientific advice, indicating progress in meeting regulatory requirements for its lead candidate.

Next Steps

• Submit a New Drug Application (NDA) to the FDA for accelerated approval of iopofosine I 131 for WM, contingent on sufficient funding and initiation of a confirmatory trial.
• Initiate a randomized Phase 3 confirmatory trial for iopofosine I 131 in WM patients, assessing progression-free survival as the primary endpoint, to support full FDA approval.
• File for a Conditional Marketing Authorization (CMA) for iopofosine I 131 as a treatment for post-BTKi refractory WM patients with the European Medicines Agency (EMA).
• Initiate a Phase 1 imaging and dose escalation safety study for CLR 225, subject to obtaining necessary additional funding.
• Continue enrollment in the CLOVER-2 Phase 1b study for iopofosine in pediatric patients with high-grade gliomas.
• Progress the Phase 1b dose finding study for CLR 125 in triple negative breast cancer, requiring additional funding for preliminary data readout.
• Actively pursue additional outside capital via the sale of equity and/or debt securities or execute a strategic transaction to improve liquidity.
• Implement temporary cost-saving measures to preserve liquidity as needed.
• Continue recruiting and hiring qualified accounting and financial reporting personnel to remediate material weaknesses in internal control over financial reporting and design a formal control environment and risk assessment process.

Key Dates

Recommendation

Cellectar Biosciences presents a compelling clinical narrative with its lead asset, iopofosine I 131, achieving FDA Breakthrough Therapy Designation and positive EMA guidance for Waldenstrom macroglobulinemia, alongside strong Phase 2 data. The significant reduction in net losses and operating expenses demonstrates improved financial discipline. However, the company's persistent 'going concern' warning, substantial cash burn, and the explicit need for significant additional funding to advance its pipeline and regulatory strategy introduce considerable financial risk. The identified material weaknesses in internal controls also raise governance concerns. While the clinical progress is promising and could lead to substantial upside upon approval, the high financial uncertainty and reliance on future capital raises make it a speculative investment. A 'hold' recommendation is appropriate for investors who are already exposed and believe in the long-term potential, but new investors should exercise extreme caution due to the significant funding risks and operational challenges.

Keywords

Cellectar Biosciences, CLRB, SEC Filing, 10-Q, Biopharmaceutical, Cancer Treatment, Phospholipid Drug Conjugate, PDC Platform, iopofosine I 131, CLR 131, Waldenstrom Macroglobulinemia, WM, Multiple Myeloma, MM, High-Grade Glioma, HGG, Triple Negative Breast Cancer, TNBC, CLR 125, CLR 225, Radioconjugate, Radiopharmaceutical, FDA Breakthrough Therapy Designation, EMA Conditional Marketing Authorization, Clinical Trials, Oncology, Financial Results, Net Loss, Research and Development, Liquidity, Going Concern, Warrants, Capital Raise, Internal Controls